Issues in selecting HCV‐infected candidates for anti‐viral treatment
dc.contributor.author | Lok, Anna S. | en_US |
dc.date.accessioned | 2012-05-21T15:49:38Z | |
dc.date.available | 2013-06-11T19:15:53Z | en_US |
dc.date.issued | 2012-04 | en_US |
dc.identifier.citation | Lok, Anna S. (2012). "Issues in selecting HCV‐infected candidates for anti‐viral treatment ." Clinical Liver Disease 1(2): 29-31. <http://hdl.handle.net/2027.42/91215> | en_US |
dc.identifier.issn | 2046-2484 | en_US |
dc.identifier.issn | 2046-2484 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/91215 | |
dc.description.abstract | Watch the interview with the authors Answer questions and earn CME | en_US |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.title | Issues in selecting HCV‐infected candidates for anti‐viral treatment | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Gastroenterology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | From the University of Michigan Health System, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/91215/1/18_ftp.pdf | |
dc.identifier.doi | 10.1002/cld.18 | en_US |
dc.identifier.source | Clinical Liver Disease | en_US |
dc.identifier.citedreference | Sarazzin C, Kieffer TL, Bartels D, Hanzeika B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767 ‐ 1777. | en_US |
dc.identifier.citedreference | Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417 ‐ 2428. | en_US |
dc.identifier.citedreference | Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski M, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy [abstract]. J Hepatol 2011; 54: S6. | en_US |
dc.identifier.citedreference | Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda A, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [abstract]. J Hepatol 2011; 54: S542. | en_US |
dc.identifier.citedreference | Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature 2009; 461: 399 ‐ 401. | en_US |
dc.identifier.citedreference | Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195 ‐ 1206. | en_US |
dc.identifier.citedreference | Jacobson IM, McHutchinson JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405 ‐ 2416. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.